Enavatuzumab (PDL192; ABT-361) is a humanized IgG1 monoclonal antibody designed to selectively target the TNF-like weak inducer of apoptosis receptor (TWEAK receptor, TweakR). This receptor is naturally engaged by its ligand TWEAK (TNFRSF12A), which activates various cellular responses. By binding to TweakR, Enavatuzumab inhibits tumor proliferation through direct receptor signaling and promotes antibody-dependent cell-mediated cytotoxicity (ADCC). This antibody has demonstrated efficacy in recruiting and activating myeloid effector cells to eradicate tumor cells. Enavatuzumab has shown to inhibit the growth of a range of human TweakR-positive cancer cell lines and xenografts both in vitro and in vivo, marking it as a potent therapeutic agent in cancer research and treatment.
Enavatuzumab (PDL192; ABT-361) is a humanized IgG1 monoclonal antibody designed to selectively target the TNF-like weak inducer of apoptosis receptor (TWEAK receptor, TweakR). This receptor is naturally engaged by its ligand TWEAK (TNFRSF12A), which activates various cellular responses. By binding to TweakR, Enavatuzumab inhibits tumor proliferation through direct receptor signaling and promotes antibody-dependent cell-mediated cytotoxicity (ADCC). This antibody has demonstrated efficacy in recruiting and activating myeloid effector cells to eradicate tumor cells. Enavatuzumab has shown to inhibit the growth of a range of human TweakR-positive cancer cell lines and xenografts both in vitro and in vivo, marking it as a potent therapeutic agent in cancer research and treatment.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
Please check COA/MSDS for correct molecular weight.
Calculate the dilution required to prepare a stock solution.This equation is commonly abbreviated as: C1V1 = C2V2
Frequently Asked Questions
What are Biosimilar Antibodies?
Biosimilar antibodies are research-grade recombinant antibodies designed to closely resemble approved therapeutic antibodies in terms of amino acid sequence, structural characteristics, and biological activity. These antibodies are generated using recombinant expression technologies and retain the same variable regions as their corresponding reference therapeutics, thereby preserving target specificity and binding affinity. Owing to these properties, biosimilar antibodies serve as reliable and cost-effective research reagents for applications in drug discovery, pharmacological studies, and basic biomedical research.
Research-grade biosimilar antibodies have been successfully expressed and functionally validated against a wide range of widely studied targets. These antibodies can be directly utilized as positive control reagents in drug discovery programs, as well as reference tools for rapid verification of the biological functions of target proteins in biochemical and cellular assays.
